Editas Medicine Reports Inducement Grant to New Chief Medical Officer
October 06 2016 - 8:00AM
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing
company, announced today the grant of an inducement award to the
company’s newly appointed Chief Medical Officer, Gerald F. Cox,
M.D., Ph.D. The award was approved by Editas’ Board of Directors on
October 5, 2016 as an inducement material to Dr. Cox entering into
employment with Editas, in accordance with NASDAQ Listing Rule
5635(c)(4).
The inducement grant to Dr. Cox consisted of an option to
purchase up to 225,000 shares of common stock. The inducement grant
is exercisable at a price of $15.48 per share, equal to the closing
price per share of Editas’ common stock as reported by NASDAQ on
October 5, 2016. The stock option vests over four years, with 25%
of the shares vesting on October 3, 2017, and the remainder vesting
ratably at the end of each subsequent month thereafter, subject to
Dr. Cox’s continued service relationship with Editas through the
applicable vesting dates.
About Editas MedicineEditas Medicine is a
leading genome editing company dedicated to treating patients with
genetically defined diseases by correcting their disease-causing
genes. The company was founded by world leaders in genome editing,
and its mission is to translate the promise of genome editing
science into a broad class of transformative genomic medicines to
benefit the greatest number of patients.
Media Contact:
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
Investor Contact:
Mark Mullikin
Editas Medicine, Inc.
(617) 401-9083
mark.mullikin@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Apr 2023 to Apr 2024